JAMA Oncology : Oncolytic Viral Immunochemotherapy in Patients With Ovarian Cancer

Interview with Robert W. Holloway, MD, and Sarfraz Ahmad, PhD, authors of Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. Hosted by Jack West, MD. Related Content: Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Source: JAMA Specialty Journals Author Interviews - May 25, 2023 Category: General Medicine Authors: The JAMA Network Source Type: podcasts